Article Text
Statistics from Altmetric.com
Goal Attainment Scaling allows for problems identified by patients and carers to be the focus of treatment
The explosion of interest in clinical trials for the treatment of the symptoms of Alzheimer’s disease has resulted in an industry developing instruments, which assess the disorder and the changes that can occur as a result of interventions.1 The ability to quantify phenomena is an essential prerequisite to measure the effects of any treatments.
The questioning of the relevance of a purely cognitive approach to monitoring change in Alzheimer’s disease—that is, the understandable doubt as to the clinical relevance of, say, remembering eight as opposed …
Footnotes
-
Competing interests: AB receives honoria from parmaceutical companies involved in the development of drugs for people with Alzheimer’s disease